A molecular perspective of CTLA-4 function.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Annual Review of Immunology

• Publication date

  2006-03-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1146/ANNUREV.IMMUNOL.24.021605.090535PMID 16551244
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Crystal structure of a soluble CD28-Fab complex

  2005cited by this paper
• Regulation of the Small GTPase Rap1 and Extracellular Signal-Regulated Kinases by the Costimulatory Molecule CTLA-4

  2005cited by this paper
• CTLA4‐CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal‐strength information to modulate activation with Concanavalin A

  2005cited by this paper
• Exocytosis of CTLA-4 Is Dependent on Phospholipase D and ADP Ribosylation Factor-1 and Stimulated during Activation of Regulatory T Cells1

  2005cited by this paper
• B7-Independent Inhibition of T Cells by CTLA-41

  2005cited by this paper
• Hierarchical Regulation of CTLA-4 Dimer-Based Lattice Formation and Its Biological Relevance for T Cell Inactivation1

  2005cited by this paper
• In vivo overexpression of CTLA‐4 suppresses lymphoproliferative diseases and thymic negative selection

  2005cited by this paper
• Cd28 and Ctla-4, two related members of the Ig supergene family, are tightly linked on proximal mouse chromosome 1

  2004cited by this paper
• Cutting Edge: Cbl-b: One of the Key Molecules Tuning CD28- and CTLA-4-Mediated T Cell Costimulation1

  2004cited by this paper
• Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA‐4 expression

  2004cited by this paper
• Structural and functional analysis of the costimulatory receptor programmed death-1.

  2004cited by this paper
• An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells.

  2004cited by this paper
• Role of CTLA-4 in the Activation of Single- and Double-Positive Thymocytes1

  2004cited by this paper
• Differential expression of CTLA‐4 among T cell subsets

  2004cited by this paper
• CD152 (CTLA-4) Determines the Unequal Resistance of Th1 and Th2 Cells against Activation-induced Cell Death by a Mechanism Requiring PI3 Kinase Function

  2004cited by this paper
• Expression of CTLA‐4 in nonhuman primate lymphocytes and its use as a potential target for specific immunotoxin‐mediated apoptosis: results of in vitro studies

  2004cited by this paper
• Distinct roles of CTLA‐4 and TGF‐β in CD4+CD25+ regulatory T cell function

  2004cited by this paper
• CTLA-4 Regulates Expansion and Differentiation of Th1 Cells Following Induction of Peripheral T Cell Tolerance1

  2004cited by this paper
• Human CD28 and CTLA-4 Ig superfamily genes are located on chromosome 2 at bands q33–q34

  2004cited by this paper
• Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity

  2004cited by this paper
• What is the importance of the immunological synapse?

  2004cited by this paper
• Tyrosine-mediated inhibitory signals contribute to CTLA-4 function in vivo.

  2004cited by this paper
• Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function.

  2004cited by this paper
• Phosphoinositide 3-kinase: diverse roles in immune cell activation.

  2004cited by this paper
• Control of Immune Responses by Trafficking Cell Surface Proteins, Vesicles and Lipid Rafts to and from the Immunological Synapse

  2004cited by this paper
• Two different forms of human CTLA-4 proteins following peripheral T cell activation.

  2004cited by this paper
• New views of the immunological synapse: variations in assembly and function.

  2004cited by this paper
• Conversion of CTLA-4 from Inhibitor to Activator of T Cells with a Bispecific Tandem Single-Chain Fv Ligand1

  2004cited by this paper
• B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse.

  2004cited by this paper
• Tolerance, DCs and tryptophan: much ado about IDO.

  2003cited by this paper
• Coordination of T Cell Activation and Migration through Formation of the Immunological Synapse

  2003cited by this paper
• CTLA-4 and tolerance

  2003cited by this paper
• Modulation of tryptophan catabolism by regulatory T cells

  2003cited by this paper
• TCR subunit specificity of CTLA‐4‐mediated signaling

  2003cited by this paper
• T cell anergy.

  2003cited by this paper
• Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling

  2003cited by this paper
• CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells.

  2003cited by this paper
• CTLA-4 regulates the requirement for cytokine-induced signals in TH2 lineage commitment

  2003cited by this paper
• Viewpoint: Therapeutic Implications of CTLA‐4 Compartmentalization

  2003cited by this paper
• Negative Regulation of T Cell Receptor–Lipid Raft Interaction by Cytotoxic T Lymphocyte–associated Antigen 4

  2003cited by this paper
• Molecular interactions mediating T cell antigen recognition.

  2003cited by this paper
• BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

  2003cited by this paper
• Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease

  2003cited by this paper
• Crystal structure of the receptor-binding domain of human B7-2: Insights into organization and signaling

  2003cited by this paper
• A Common Autoimmunity Predisposing Signal Peptide Variant of the Cytotoxic T-lymphocyte Antigen 4 Results in Inefficient Glycosylation of the Susceptibility Allele*

  2002cited by this paper
• The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses.

  2002cited by this paper
• Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength.

  2002cited by this paper
• CTLA-4 Negative Signaling via Lipid Rafts: A New Perspective

  2002cited by this paper
• Surface Cytotoxic T Lymphocyte–associated Antigen 4 Partitions Within Lipid Rafts and Relocates to the Immunological Synapse under Conditions of Inhibition of T Cell Activation

  2002cited by this paper
• Expression of CTLA‐4 by Human Monocytes

  2002cited by this paper
• A CTLA-4 gene polymorphism at position −318 in the promoter region affects the expression of protein

  2002cited by this paper
• CTLA-4–Ig regulates tryptophan catabolism in vivo

  2002cited by this paper
• Clustering of MHC–peptide complexes prior to their engagement in the immunological synapse: lipid raft and tetraspan microdomains

  2002cited by this paper
• The interaction properties of costimulatory molecules revisited.

  2002cited by this paper
• Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation.

  2002cited by this paper
• Protein phosphatase 2A is the main phosphatase involved in the regulation of protein kinase B in rat adipocytes.

  2002cited by this paper
• Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors

  2002cited by this paper
• Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence.

  2002cited by this paper
• IFN-gamma regulates murine interferon-inducible T cell alpha chemokine (I-TAC) expression in dendritic cell lines and during experimental autoimmune encephalomyelitis (EAE).

  2002cited by this paper
• CD28 Costimulation Mediates Down-Regulation of p27kip1 and Cell Cycle Progression by Activation of the PI3K/PKB Signaling Pathway in Primary Human T Cells1

  2002cited by this paper
• Re-establishing Peripheral Tolerance in the Absence of CTLA-4: Complementation by Wild-Type T Cells Points to an Indirect Role for CTLA-41

  2002cited by this paper
• Structural mechanisms of costimulation

  2002cited by this paper
• Reduced CTLA-4 protein and messenger RNA expression in umbilical cord blood T lymphocytes.

  2002cited by this paper
• Protein kinase B (Akt) regulation and function in T lymphocytes.

  2002cited by this paper
• CTLA-4 Suppresses Proximal TCR Signaling in Resting Human CD4+ T Cells by Inhibiting ZAP-70 Tyr319 Phosphorylation: A Potential Role for Tyrosine Phosphatases1

  2002cited by this paper
• Cutting Edge: CTLA-4 (CD152) Differentially Regulates Mitogen-Activated Protein Kinases (Extracellular Signal-Regulated Kinase and c-Jun N-Terminal Kinase) in CD4+ T Cells from Receptor/Ligand-Deficient Mice1

  2002cited by this paper
• Inhibition of CTLA-4 Function by the Regulatory Subunit of Serine/Threonine Phosphatase 2A1

  2002cited by this paper
• The role of CTLA‐4 in induction and maintenance of peripheral T cell tolerance

  2002cited by this paper
• Cyclic Adenosine 5′-Monophosphate and Calcium Induce CD152 (CTLA-4) Up-Regulation in Resting CD4+ T Lymphocytes

  2002cited by this paper
• Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses

  2001cited by this paper
• Normal pathogen‐specific immune responses mounted by CTLA‐4‐deficient T cells: a paradigm reconsidered

  2001cited by this paper
• PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine

  2001cited by this paper
• Structural basis for co-stimulation by the human CTLA-4/B7-2 complex

  2001cited by this paper
• Protein phosphatase 2A: variety of forms and diversity of functions.

  2001cited by this paper
• The role of Rap1 in integrin-mediated cell adhesion.

  2001cited by this paper
• Co-stimulation and counter-stimulation: lipid raft clustering controls TCR signaling and functional outcomes.

  2001cited by this paper
• Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-γ but not TH2 cytokines

  2001cited by this paper
• Protein phosphatase 2A: the Trojan Horse of cellular signaling.

  2001cited by this paper
• Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation.

  2001cited by this paper
• CTLA-4 regulates induction of anergy in vivo.

  2001cited by this paper
• Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy.

  2001cited by this paper
• CD150 Association with Either the SH2-Containing Inositol Phosphatase or the SH2-Containing Protein Tyrosine Phosphatase Is Regulated by the Adaptor Protein SH2D1A1

  2001cited by this paper
• Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling.

  2001cited by this paper
• Regulation of Surface and Intracellular Expression of CTLA‐4 on Human Peripheral T Cells

  2001cited by this paper
• Antagonistic Roles for CTLA-4 and the Mammalian Target of Rapamycin in the Regulation of Clonal Anergy: Enhanced Cell Cycle Progression Promotes Recall Antigen Responsiveness1

  2001cited by this paper
• Src kinases Fyn and Lck facilitate the accumulation of phosphorylated CTLA-4 and its association with PI-3 kinase in intracellular compartments of T-cells.

  2001cited by this paper
• A role for protein phosphatase 2A-like activity, but not atypical protein kinase Czeta, in the inhibition of protein kinase B/Akt and glycogen synthesis by palmitate.

  2001cited by this paper
• CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.

  2001cited by this paper
• A regulatory role for cytoplasmic YVKM motif in CTLA‐4 inhibition of TCR signaling

  2001cited by this paper
• T-cell regulation by CD28 and CTLA-4

  2001cited by this paper
• Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4

  2000cited by this paper
• Polarization of Naive CD4+ T Cells Toward the Th1 Subset by CTLA-4 Costimulation1

  2000cited by this paper
• Inhibition of IgG1 and IgE Production by Stimulation of the B Cell CTLA-4 Receptor1

  2000cited by this paper
• The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A.

  2000cited by this paper
• Molecular cloning and expression of feline CD28 and CTLA-4 cDNA.

  2000cited by this paper
• CD28 Utilizes Vav-1 to Enhance TCR-Proximal Signaling and NF-AT Activation1

  2000cited by this paper
• Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b

  2000cited by this paper
• A native soluble form of CTLA-4.

  2000cited by this paper
• CTLA-4 (CD152) Can Inhibit T Cell Activation by Two Different Mechanisms Depending on Its Level of Cell Surface Expression1

  2000cited by this paper
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

  2000cited by this paper

• Clathrin mediated endocytosis targeting chimera for targeted membrane proteins degradation and enhance CAR-T cell anti-tumor therapy

  2026cites this paper
• Screening of a pooled library of chimeric antigen receptor T cells based on secretory function

  2025cites this paper
• High-throughput discovery of transmembrane helix dimers from human single-pass membrane proteins with TOXGREEN sort-seq

  2025cites this paper
• Immune checkpoint inhibitor-related arthritis and oral disorders: shared pathophysiology and clinical implications for rheumatology and oral health

  2025cites this paper
• Alternative Splicing: A Key Regulator in T cell Response and Cancer Immunotherapy.

  2025cites this paper
• Single-cell RNA sequencing of bone marrow reveals the immune response mechanisms of lymphocytes under avian leukosis virus subgroup J infection

  2025cites this paper
• Functional genetic variants in immune-checkpoint molecules and susceptibility to Nasopharyngeal carcinoma in a Tunisian case-control study

  2025cites this paper
• Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple Myeloma

  2025cites this paper
• Novel pathogenic variants in CTLA4 and LRBA immune dysregulation: Reduced CTLA-4 expression with normal expression of co-stimulatory surface molecules.

  2025cites this paper
• Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications

  2025cites this paper
• The pathogenesis of neurological immune-related adverse events following immune checkpoint inhibitor therapy.

  2025cites this paper
• Mechanisms and Clinical Implications of Immune Checkpoint Inhibitors PD-1, CTLA-4, and TIM-3 in Cancer

  2025influential citation
• Myeloid Cells Induce Infiltration and Activation of B Cells and CD4+ T Follicular Helper Cells to Sensitize Brain Metastases to Combination Immunotherapy.

  2025cites this paper
• Enhancement of antitumor immunity by CTLA-4 antisense oligonucleotides with CpG motif in mice.

  2025cites this paper
• High-throughput discovery of transmembrane helix dimers from human single-pass membrane proteins with TOXGREEN sort-seq

  2025cites this paper
• Cytotoxic T lymphocyte-associated protein 4 gene polymorphisms are associated with ANCA-associated vasculitis in the Guangxi population of China

  2025cites this paper
• Treg Cell Therapeutic Strategies for Breast Cancer: Holistic to Local Aspects

  2024cites this paper
• Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes

  2024cites this paper
• Association between Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4) Locus and Early-Onset Anti-acetylcholine Receptor-Positive Myasthenia Gravis in Serbian Patients

  2024cites this paper
• Immune checkpoints in B-cell Lymphoma: Still an Unmet challenge from Basic research to clinical practice.

  2024cites this paper
• Impact of Chemotherapeutic Agents on PD-L1, CTLA-4, and VISTA Gene Expression in Cervical Cancer Cell Lines: An In Vitro Study

  2024cites this paper
• VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms

  2024cites this paper
• Potential Plasma Proteins (LGALS9, LAMP3, PRSS8 and AGRN) as Predictors of Hospitalisation Risk in COVID-19 Patients

  2024cites this paper
• Structural basis for the immune recognition and selectivity of the immune receptor PVRIG for ligand Nectin-2.

  2024cites this paper
• Exploring the Immunoresponse in Bladder Cancer Immunotherapy

  2024cites this paper
• Blockade of V‐domain immunoglobulin suppressor of T‐cell activation reprograms tumour‐associated macrophages and improves efficacy of PD‐1 inhibitor in gastric cancer

  2024cites this paper
• Mechanistic Insights into the Inhibition of a Common CTLA-4 Gene Mutation in the Cytoplasmic Domain

  2024cites this paper
• Higher relapse and worse overall survival in recipients with CTLA-4 AA genotype of rs231775 following single-unit cord blood transplantation in adults

  2024cites this paper
• A comprehensive review of immune checkpoint inhibitors for cancer treatment.

  2024cites this paper
• Nanoparticles targeting immune checkpoint protein VISTA induce potent antitumor immunity

  2024cites this paper
• Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment

  2024cites this paper
• Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers

  2023cites this paper
• Computational analysis of structural and functional evaluation of the deleterious missense variants in the human CTLA4 gene

  2023cites this paper
• Impact of the cytotoxic T-lymphocyte associated antigen-4 rs231775 A/G polymorphism on cancer risk

  2023cites this paper
• Functional Relevance of CTLA4 Variants: an Upgraded Approach to Assess CTLA4-Dependent Transendocytosis by Flow Cytometry

  2023cites this paper
• Influence of B7 costimulatory molecules colocalized in Extracellular Traps (ETs) on the expression of CD45RO in neutrophils and CD4 lymphocytes in human autologous cultures

  2023cites this paper
• Soluble CTLA-4 raises the threshold for T-cell activation and modulates anti-tumour immunity

  2023cites this paper
• Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials

  2023cites this paper
• New Therapies in Melanoma: Current Trends, Evolving Paradigms, and Future Perspectives.

  2023cites this paper
• Local Delivery of Immunomodulatory Antibodies for Gastrointestinal Tumors

  2023cites this paper
• Effect of neoadjuvant chemotherapy on tumor immune infiltration in breast cancer patients: Systematic review and meta-analysis

  2023cites this paper
• Checkpoint blockade meets gene therapy: Opportunities to improve response and reduce toxicity.

  2023cites this paper
• Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?

  2023cites this paper
• Current understanding of CTLA-4: from mechanism to autoimmune diseases

  2023cites this paper
• Construction and validation of a prognosis signature based on the immune microenvironment in gastric cancer

  2023cites this paper
• Deletion of the inhibitory co-receptor CTLA4 enhances and invigorates chimeric antigen receptor T cells.

  2023cites this paper
• Development of a Molecular-Subtype-Associated Immune Prognostic Signature That Can Be Recognized by MRI Radiomics Features in Bladder Cancer

  2023cites this paper
• Evidence of Association between CTLA-4 Gene Polymorphisms and Colorectal Cancers in Saudi Patients

  2023cites this paper
• Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity

  2023cites this paper
• Exosomal microRNAs in cancer: Potential biomarkers and immunotherapeutic targets for immune checkpoint molecules

  2023cites this paper
• What do we know about co-stimulatory and co-inhibitory immune checkpoint signals in ankylosing spondylitis?

  2023cites this paper
• CTLA4 depletes T cell endogenous and trogocytosed B7 ligands via cis-endocytosis

  2023cites this paper
• Blood regulatory T cells in inflammatory bowel disease, a systematic review, and meta-analysis.

  2023cites this paper
• Resistance to immune checkpoint inhibitors and the tumor microenvironment

  2022cites this paper
• Immunotherapeutic strategies to induce inflection in the immune response: therapy for cancer and COVID-19

  2022cites this paper
• The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies

  2022cites this paper
• Therapeutic Advances in Immunotherapies for Hematological Malignancies

  2022cites this paper
• Costimulatory and coinhibitory molecules of B7-CD28 family in cardiovascular atherosclerosis: A review

  2022cites this paper
• Delivery of antigen to porcine dendritic cells by fusing antigen with porcine dendritic cells targeting peptide

  2022cites this paper
• Association of Cytotoxic T-Lymphocyte Antigen-4 Gene Polymorphism with Type 1 Diabetes Mellitus: In silico Analysis of Biological Features of CTLA-4 Protein on Ethiopian Population

  2022influential citation
• The role of immune regulatory molecules in rheumatoid arthritis: Implication for etiopathogenesis and prospective for treatment

  2022cites this paper
• Genome-wide association study of hyperthyroidism based on electronic medical record from Taiwan

  2022cites this paper
• Advance of T regulatory cells in tumor microenvironment remodeling and immunotherapy in pancreatic cancer

  2022cites this paper
• Development of Cancer Immunotherapies.

  2022cites this paper
• Survey of the association between polymorphisms of CTLA-4 exon 1 49 A/G genes with rheumatoid arthritis in Iran

  2022cites this paper
• Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer

  2022influential citation
• Differential early diagnosis of benign versus malignant lung cancer using systematic pathway flux analysis of peripheral blood leukocytes

  2022cites this paper
• Pathology of T-cell-mediated drug hypersensitivity reactions and impact of tolerance mechanisms on patient susceptibility.

  2022cites this paper
• Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab.

  2022cites this paper
• CTLA-4 Facilitates DNA Damage–Induced Apoptosis by Interacting With PP2A

  2022cites this paper
• Aire suppresses CTLA-4 expression from the thymic stroma to control autoimmunity.

  2022cites this paper
• Innate Immunomodulatory Nanodevices for Cancer Therapy: A Review.

  2022cites this paper
• Therapeutic strategies

  2021cites this paper
• Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers

  2021influential citation
• Association of cytotoxic T-lymphocyte antigen-4 (CTLA-4) single nucleotide polymorphism in donors with clinical outcome after allogeneic hematopoietic stem cell transplantation: a meta-analysis

  2021cites this paper
• Clinical Experience with CTLA-4 Blockade for Cancer Immunotherapy: From the Monospecific Monoclonal Antibody Ipilimumab to Probodies and Bispecific Molecules Targeting The Tumor Microenvironment.

  2021cites this paper
• ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors

  2021cites this paper
• Hashimoto’s Thyroiditis and Graves’ Disease in Genetic Syndromes in Pediatric Age

  2021cites this paper
• Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management

  2021influential citation
• Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis

  2021cites this paper
• Identification and characterization of CD152 in Nile tilapia (Oreochromis niloticus) playing roles in host immune response against bacterial pathogens

  2021cites this paper
• Pulmonary Toxicities of Immunotherapy.

  2021cites this paper
• Psoriasis Susceptibility 1 Candidate 1 (PSORS1C1) Polymorphism is Associated with Autoimmune Thyroid Disease in a Chinese Han Population

  2021cites this paper
• Antibody Therapies for Large B-Cell Lymphoma

  2021cites this paper
• IPEX Syndrome and IPEX-Related Disorders

  2021cites this paper
• Evaluation of Candidate SNPs for Type 2 Diabetes Mellitus in Tohid Hospital of Sanandaj.

  2021cites this paper
• Kostimulatorische und -inhibitorische Signale für T-Zellen

  2021cites this paper
• Immunotherapy and predictive immunologic profile: the tip of the iceberg

  2021cites this paper
• T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies

  2021cites this paper
• Antigenic Challenge Influences Epigenetic Changes in Antigen-Specific T Regulatory Cells

  2021cites this paper
• Therapeutic Targeting of Checkpoint Receptors within the DNAM-1 Axis.

  2021influential citation
• Emerging Immunotherapy for Acute Myeloid Leukemia

  2021cites this paper
• Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab

  2021cites this paper
• Type 1 Diabetes and Autoimmune Thyroid Disease—The Genetic Link

  2021cites this paper
• Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?

  2021cites this paper
• Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy

  2021cites this paper
• Genetic Susceptibility to Joint Occurrence of Polycystic Ovary Syndrome and Hashimoto’s Thyroiditis: How Far Is Our Understanding?

  2021cites this paper
• Up-regulation of circRNA-0003528 promotes mycobacterium tuberculosis associated macrophage polarization via down-regulating miR-224-5p, miR-324-5p and miR-488-5p and up-regulating CTLA4

  2020cites this paper
• Structure Prediction and Expression of Modified rCTLA4-Ig as a Blocker for B7 Molecules

  2020cites this paper
• New landscapes and horizons in hepatocellular carcinoma therapy

  2020cites this paper